O	0	5	Phase
O	6	9	III
O	10	15	study
O	16	18	to
O	19	27	evaluate
O	28	31	the
O	32	35	use
O	36	38	of
B-intervention	39	43	high
I-intervention	43	44	-
I-intervention	44	48	dose
I-intervention	49	61	chemotherapy
O	62	64	as
O	65	78	consolidation
O	79	81	of
O	82	91	treatment
O	92	95	for
O	96	100	high
O	100	101	-
O	101	105	risk
O	106	119	postoperative
O	120	126	breast
O	127	133	cancer
O	133	134	:
O	135	140	Japan
O	141	149	Clinical
O	150	158	Oncology
O	159	164	Group
O	165	170	study
O	170	171	,
O	172	176	JCOG
O	177	181	9208
O	181	182	.

O	183	184	A
O	185	195	randomized
O	196	206	controlled
O	207	212	trial
O	213	216	was
O	217	226	conducted
O	227	229	to
O	230	238	evaluate
O	239	242	the
O	243	251	efficacy
O	252	254	of
O	255	259	high
O	259	260	-
O	260	264	dose
O	265	277	chemotherapy
O	278	279	(
O	279	282	HDC
O	282	283	)
O	284	286	as
O	287	300	consolidation
O	301	303	of
O	304	307	the
O	308	317	treatment
O	318	320	of
O	321	325	high
O	325	326	-
O	326	330	risk
O	331	344	postoperative
O	345	351	breast
O	352	358	cancer
O	358	359	.

O	360	368	Patients
B-age	369	374	under
I-age	375	377	56
I-age	378	383	years
O	384	386	of
O	387	390	age
B-eligibility	391	395	with
I-eligibility	396	401	stage
I-eligibility	402	403	I
I-eligibility	404	406	to
I-eligibility	407	411	IIIB
I-eligibility	412	418	breast
I-eligibility	419	425	cancer
I-eligibility	426	435	involving
I-eligibility	436	438	10
I-eligibility	439	441	or
I-eligibility	442	446	more
I-eligibility	447	455	axillary
I-eligibility	456	461	lymph
I-eligibility	462	467	nodes
O	468	472	were
O	473	481	eligible
O	481	482	.

O	483	486	The
O	487	494	primary
O	495	503	endpoint
O	504	507	was
B-outcome-Measure	508	515	relapse
I-outcome-Measure	515	516	-
I-outcome-Measure	516	520	free
I-outcome-Measure	521	529	survival
I-outcome-Measure	530	531	(
I-outcome-Measure	531	534	RFS
I-outcome-Measure	534	535	)
O	535	536	.

O	537	544	Between
O	545	548	May
O	549	553	1993
O	554	557	and
O	558	563	March
O	564	568	1999
O	568	569	,
B-total-participants	570	572	97
O	573	581	patients
O	582	586	were
O	587	595	enrolled
O	595	596	,
O	597	600	and
O	601	604	two
O	605	613	patients
O	614	620	became
O	621	631	ineligible
O	631	632	.

O	633	636	The
O	637	643	median
O	644	647	age
O	648	650	of
O	651	654	the
O	655	657	97
O	658	666	patients
O	667	670	was
O	671	673	46
O	674	679	years
O	680	681	(
O	681	686	range
O	687	689	27
O	689	690	-
O	690	692	55
O	693	698	years
O	698	699	)
O	699	700	,
O	701	704	and
O	705	707	72
O	708	709	(
O	709	711	74
O	711	712	%
O	712	713	)
O	714	718	were
O	719	732	premenopausal
O	732	733	.

O	734	737	The
O	738	744	median
O	745	751	number
O	752	754	of
O	755	763	involved
O	764	772	axillary
O	773	778	nodes
O	779	782	was
O	783	785	16
O	786	787	(
O	787	792	range
O	793	795	10
O	795	796	-
O	796	798	49
O	798	799	)
O	799	800	.

O	801	804	All
O	805	813	patients
O	814	817	had
O	818	827	undergone
O	828	829	a
O	830	837	radical
O	838	848	mastectomy
O	848	849	.

O	850	855	Major
O	856	871	characteristics
O	872	876	were
O	877	881	well
O	882	890	balanced
O	891	898	between
O	899	902	the
O	903	912	treatment
O	913	917	arms
O	917	918	.

B-control-participants	919	924	Forty
I-control-participants	924	925	-
I-control-participants	925	930	eight
O	931	939	patients
O	940	942	in
O	943	946	the
B-control	947	955	standard
I-control	955	956	-
I-control	956	960	dose
I-control	961	962	(
I-control	962	965	STD
I-control	965	966	)
O	967	970	arm
O	971	979	received
O	980	983	six
O	984	991	courses
O	992	994	of
O	995	1011	cyclophosphamide
O	1011	1012	,
O	1013	1024	doxorubicin
O	1024	1025	,
O	1026	1029	and
O	1030	1031	5
O	1031	1032	-
O	1032	1044	fluorouracil
O	1045	1053	followed
O	1054	1056	by
O	1057	1066	tamoxifen
O	1066	1067	.

B-intervention-participants	1068	1073	Forty
I-intervention-participants	1073	1074	-
I-intervention-participants	1074	1078	nine
O	1079	1087	patients
O	1088	1092	were
O	1093	1101	assigned
O	1102	1104	to
O	1105	1112	undergo
O	1113	1116	HDC
O	1117	1121	with
O	1122	1138	cyclophosphamide
O	1139	1142	and
O	1143	1151	thiotepa
O	1152	1157	after
O	1158	1161	six
O	1162	1169	courses
O	1170	1172	of
O	1173	1189	cyclophosphamide
O	1189	1190	,
O	1191	1202	doxorubicin
O	1202	1203	,
O	1204	1207	and
O	1208	1209	5
O	1209	1210	-
O	1210	1222	fluorouracil
O	1223	1231	followed
O	1232	1234	by
O	1235	1244	tamoxifen
O	1244	1245	;
O	1246	1253	however
O	1253	1254	,
O	1255	1257	15
O	1258	1260	of
O	1261	1266	these
O	1267	1275	patients
O	1276	1277	(
O	1277	1279	31
O	1279	1280	%
O	1280	1281	)
O	1282	1285	did
O	1286	1289	not
O	1290	1297	undergo
O	1298	1301	HDC
O	1301	1302	.

O	1303	1306	HDC
O	1307	1310	was
B-outcome	1311	1315	well
I-outcome	1316	1325	tolerated
O	1326	1333	without
O	1334	1337	any
O	1338	1347	treatment
O	1347	1348	-
O	1348	1355	related
O	1356	1365	mortality
O	1365	1366	.

O	1367	1369	At
O	1370	1371	a
O	1372	1378	median
O	1379	1385	follow
O	1385	1386	-
O	1386	1388	up
O	1389	1391	of
O	1392	1394	63
O	1395	1401	months
O	1401	1402	,
O	1403	1406	the
B-outcome	1407	1408	5
I-outcome	1408	1409	-
I-outcome	1409	1413	year
I-outcome	1414	1417	RFS
O	1418	1420	of
B-control-participants	1421	1423	47
O	1424	1432	eligible
O	1433	1441	patients
O	1442	1444	in
O	1445	1448	the
O	1449	1452	STD
O	1453	1456	arm
O	1457	1460	and
B-intervention-participants	1461	1463	48
O	1464	1472	eligible
O	1473	1481	patients
O	1482	1484	in
O	1485	1488	the
O	1489	1492	HDC
O	1493	1496	arm
O	1497	1500	was
B-cv-bin-percent	1501	1503	37
I-cv-bin-percent	1503	1504	%
O	1505	1508	and
B-iv-bin-percent	1509	1511	52
I-iv-bin-percent	1511	1512	%
O	1513	1515	on
O	1516	1518	an
O	1519	1525	intent
O	1525	1526	-
O	1526	1528	to
O	1528	1529	-
O	1529	1534	treat
O	1535	1540	basis
O	1540	1541	,
O	1542	1554	respectively
O	1555	1556	(
O	1556	1557	P
O	1558	1559	=
O	1560	1561	0
O	1561	1562	.
O	1562	1564	17
O	1564	1565	)
O	1565	1566	.

B-outcome	1567	1571	Five
I-outcome	1571	1572	-
I-outcome	1572	1576	year
I-outcome	1577	1584	overall
I-outcome	1585	1593	survival
O	1594	1596	of
O	1597	1600	all
O	1601	1611	randomized
O	1612	1620	patients
O	1621	1624	was
B-cv-bin-percent	1625	1627	62
I-cv-bin-percent	1627	1628	%
O	1629	1632	for
O	1633	1636	the
O	1637	1640	STD
O	1641	1644	arm
O	1645	1648	and
B-iv-bin-percent	1649	1651	63
I-iv-bin-percent	1651	1652	%
O	1653	1656	for
O	1657	1660	the
O	1661	1664	HDC
O	1665	1668	arm
O	1669	1670	(
O	1670	1671	P
O	1672	1673	=
O	1674	1675	0
O	1675	1676	.
O	1676	1678	78
O	1678	1679	)
O	1679	1680	.

O	1681	1689	Although
O	1690	1693	the
O	1694	1706	prespecified
O	1707	1713	values
O	1714	1716	of
O	1717	1720	the
O	1721	1724	two
O	1725	1729	arms
O	1730	1734	were
O	1735	1738	not
O	1739	1741	so
O	1742	1750	accurate
O	1751	1753	as
O	1754	1756	to
O	1757	1762	allow
O	1763	1772	detection
O	1773	1775	of
O	1776	1779	the
O	1780	1788	observed
O	1789	1799	difference
O	1799	1800	,
O	1801	1803	no
O	1804	1813	advantage
O	1814	1816	of
O	1817	1820	HDC
O	1821	1824	was
O	1825	1833	observed
O	1834	1836	in
O	1837	1842	terms
O	1843	1845	of
O	1846	1849	RFS
O	1850	1852	or
O	1853	1860	overall
O	1861	1869	survival
O	1869	1870	.
